- Home
- FOR vs SNDX Comparison
FOR vs SNDX Comparison
Compare FOR & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOR
- SNDX
- Stock Information
- Founded
- FOR 2005
- SNDX 2005
- Country
- FOR United States
- SNDX United States
- Employees
- FOR N/A
- SNDX N/A
- Industry
- FOR Real Estate
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- FOR Finance
- SNDX Health Care
- Exchange
- FOR Nasdaq
- SNDX Nasdaq
- Market Cap
- FOR 1.0B
- SNDX 1.1B
- IPO Year
- FOR 2007
- SNDX 2016
- Fundamental
- Price
- FOR $20.88
- SNDX $8.73
- Analyst Decision
- FOR Strong Buy
- SNDX Strong Buy
- Analyst Count
- FOR 3
- SNDX 10
- Target Price
- FOR $30.33
- SNDX $35.80
- AVG Volume (30 Days)
- FOR 142.8K
- SNDX 1.8M
- Earning Date
- FOR 07-22-2025
- SNDX 07-31-2025
- Dividend Yield
- FOR N/A
- SNDX N/A
- EPS Growth
- FOR N/A
- SNDX N/A
- EPS
- FOR 3.29
- SNDX N/A
- Revenue
- FOR $1,471,000,000.00
- SNDX $43,722,000.00
- Revenue This Year
- FOR $3.95
- SNDX $426.77
- Revenue Next Year
- FOR $8.86
- SNDX $98.31
- P/E Ratio
- FOR $6.36
- SNDX N/A
- Revenue Growth
- FOR N/A
- SNDX N/A
- 52 Week Low
- FOR $18.00
- SNDX $8.58
- 52 Week High
- FOR $37.21
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- FOR 56.39
- SNDX 36.15
- Support Level
- FOR $19.88
- SNDX $8.77
- Resistance Level
- FOR $21.92
- SNDX $9.50
- Average True Range (ATR)
- FOR 0.67
- SNDX 0.54
- MACD
- FOR 0.17
- SNDX -0.04
- Stochastic Oscillator
- FOR 60.90
- SNDX 8.71
About FOR Forestar Group Inc
Forestar Group Inc is a residential lot development company with operations across the United States. The core business segment for the company is real estate which generates all of it's revenues. The firm fundamentally acquires entitled real estate and develops it into finished residential lots for sale to homebuilders with a strategic focus on asset turns and efficiency. Single-family residential communities account for the majority of their real estate projects. The company utilizes a lower-risk business model mainly by investing in short duration, phased development projects.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.